Ozanimod in relapsing forms of multiple sclerosis: a profile of its use

AbstractOzanimod (Zeposia®), a sphingosine 1-phosphate (S1P) receptor modulator with high selectivity for S1P receptor subtypes  1 and 5 (S1P1 and S1P5), represents another oral disease-modifying therapy option for the treatment of relapsing forms of multiple sclerosis (MS) in adults. In two randomised, double-blind, phase  3 clinical trials, once-daily oral ozanimod 0.92 mg significantly reduced annualised relapse rates and MRI lesion accumulation compared with once-weekly intramuscular interferon β-1a 30 µg. Furthermore, an ongoing open-label extension study provides evidence that the therapeutic effects of oz animod are sustained in the longer term. Ozanimod is generally well tolerated. The once-daily oral administration provides a convenient dosing regimen, and the high selectivity for S1P1 and S1P5 receptors has the potential to improve safety by reducing potential off-target effects.
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research